nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.393	1	CiPCiCtD
Regorafenib—RAF1—Vemurafenib—melanoma	0.0992	0.47	CbGbCtD
Regorafenib—EPHA2—melanoma	0.0887	0.338	CbGaD
Regorafenib—BRAF—Vemurafenib—melanoma	0.083	0.393	CbGbCtD
Regorafenib—FLT1—melanoma	0.0445	0.17	CbGaD
Regorafenib—PDGFRA—melanoma	0.0359	0.137	CbGaD
Regorafenib—BRAF—melanoma	0.0328	0.125	CbGaD
Regorafenib—KDR—melanoma	0.0279	0.106	CbGaD
Regorafenib—KIT—melanoma	0.0263	0.1	CbGaD
Regorafenib—ABCG2—Vemurafenib—melanoma	0.00941	0.0446	CbGbCtD
Regorafenib—Keratoacanthoma—Vemurafenib—melanoma	0.00666	0.187	CcSEcCtD
Regorafenib—ABCG2—Dactinomycin—melanoma	0.00625	0.0296	CbGbCtD
Regorafenib—ABCB1—melanoma	0.00607	0.0231	CbGaD
Regorafenib—CYP3A4—Temozolomide—melanoma	0.00371	0.0176	CbGbCtD
Regorafenib—ABCG2—Docetaxel—melanoma	0.00323	0.0153	CbGbCtD
Regorafenib—ABCB1—Dactinomycin—melanoma	0.00225	0.0107	CbGbCtD
Regorafenib—CYP3A4—Vemurafenib—melanoma	0.00203	0.00964	CbGbCtD
Regorafenib—Squamous cell carcinoma—Vemurafenib—melanoma	0.00177	0.0496	CcSEcCtD
Regorafenib—DDR2—skin epidermis—melanoma	0.00134	0.0533	CbGeAlD
Regorafenib—ABCB1—Docetaxel—melanoma	0.00116	0.00552	CbGbCtD
Regorafenib—FLT1—umbilical vein—melanoma	0.000974	0.0386	CbGeAlD
Regorafenib—DDR2—hair follicle—melanoma	0.000959	0.038	CbGeAlD
Regorafenib—KDR—umbilical vein—melanoma	0.000824	0.0327	CbGeAlD
Regorafenib—Exfoliative rash—Docetaxel—melanoma	0.000786	0.0221	CcSEcCtD
Regorafenib—KDR—hindlimb—melanoma	0.000754	0.0299	CbGeAlD
Regorafenib—CYP3A4—Docetaxel—melanoma	0.000697	0.00331	CbGbCtD
Regorafenib—FGFR2—skin epidermis—melanoma	0.000687	0.0272	CbGeAlD
Regorafenib—Polyp—Vemurafenib—melanoma	0.00066	0.0185	CcSEcCtD
Regorafenib—KDR—appendage—melanoma	0.000647	0.0256	CbGeAlD
Regorafenib—Cyst—Vemurafenib—melanoma	0.0006	0.0168	CcSEcCtD
Regorafenib—FLT4—endothelium—melanoma	0.000594	0.0236	CbGeAlD
Regorafenib—Traumatic liver injury—Temozolomide—melanoma	0.000551	0.0154	CcSEcCtD
Regorafenib—FLT4—blood vessel—melanoma	0.000548	0.0217	CbGeAlD
Regorafenib—Gastrointestinal perforation—Docetaxel—melanoma	0.000523	0.0147	CcSEcCtD
Regorafenib—Hepatotoxicity—Vemurafenib—melanoma	0.00052	0.0146	CcSEcCtD
Regorafenib—DDR2—eye—melanoma	0.000478	0.019	CbGeAlD
Regorafenib—TEK—endothelium—melanoma	0.000478	0.0189	CbGeAlD
Regorafenib—KIT—skin epidermis—melanoma	0.000477	0.0189	CbGeAlD
Regorafenib—DDR2—retina—melanoma	0.000474	0.0188	CbGeAlD
Regorafenib—FLT1—endothelium—melanoma	0.000462	0.0183	CbGeAlD
Regorafenib—Sorafenib—FLT1—melanoma	0.000458	0.257	CrCbGaD
Regorafenib—EPHA2—blood vessel—melanoma	0.000452	0.0179	CbGeAlD
Regorafenib—RAF1—hair follicle—melanoma	0.000451	0.0179	CbGeAlD
Regorafenib—TEK—blood vessel—melanoma	0.000441	0.0175	CbGeAlD
Regorafenib—Mucosal inflammation—Bleomycin—melanoma	0.000439	0.0123	CcSEcCtD
Regorafenib—FLT1—blood vessel—melanoma	0.000426	0.0169	CbGeAlD
Regorafenib—DDR2—skin of body—melanoma	0.000416	0.0165	CbGeAlD
Regorafenib—Lymphopenia—Temozolomide—melanoma	0.000401	0.0112	CcSEcCtD
Regorafenib—KDR—endothelium—melanoma	0.00039	0.0155	CbGeAlD
Regorafenib—Hypomagnesaemia—Bleomycin—melanoma	0.000383	0.0107	CcSEcCtD
Regorafenib—DDR2—mammalian vulva—melanoma	0.00038	0.0151	CbGeAlD
Regorafenib—Nail disorder—Bleomycin—melanoma	0.000375	0.0105	CcSEcCtD
Regorafenib—Sorafenib—PDGFRA—melanoma	0.000369	0.207	CrCbGaD
Regorafenib—Neoplasm—Vemurafenib—melanoma	0.000363	0.0102	CcSEcCtD
Regorafenib—KDR—blood vessel—melanoma	0.00036	0.0143	CbGeAlD
Regorafenib—KIT—endothelium—melanoma	0.000346	0.0137	CbGeAlD
Regorafenib—RET—neck—melanoma	0.000346	0.0137	CbGeAlD
Regorafenib—Sorafenib—BRAF—melanoma	0.000337	0.189	CrCbGaD
Regorafenib—FGFR2—neck—melanoma	0.000329	0.013	CbGeAlD
Regorafenib—EPHX2—eye—melanoma	0.000323	0.0128	CbGeAlD
Regorafenib—EPHX2—retina—melanoma	0.00032	0.0127	CbGeAlD
Regorafenib—KIT—blood vessel—melanoma	0.000319	0.0127	CbGeAlD
Regorafenib—Cyst—Carmustine—melanoma	0.000318	0.0089	CcSEcCtD
Regorafenib—PDGFRB—blood vessel—melanoma	0.000312	0.0124	CbGeAlD
Regorafenib—FLT1—neck—melanoma	0.000305	0.0121	CbGeAlD
Regorafenib—RAF1—neck—melanoma	0.000303	0.012	CbGeAlD
Regorafenib—Hepatotoxicity—Dactinomycin—melanoma	0.000294	0.00824	CcSEcCtD
Regorafenib—FLT4—eye—melanoma	0.000291	0.0116	CbGeAlD
Regorafenib—Sorafenib—KDR—melanoma	0.000287	0.161	CrCbGaD
Regorafenib—Hepatotoxicity—Carmustine—melanoma	0.000275	0.00771	CcSEcCtD
Regorafenib—DDR2—head—melanoma	0.000272	0.0108	CbGeAlD
Regorafenib—Sorafenib—KIT—melanoma	0.000271	0.152	CrCbGaD
Regorafenib—Dry skin—Vemurafenib—melanoma	0.000267	0.00749	CcSEcCtD
Regorafenib—Lymphopenia—Docetaxel—melanoma	0.000267	0.00748	CcSEcCtD
Regorafenib—Hepatotoxicity—Temozolomide—melanoma	0.000266	0.00745	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.000262	0.00736	CcSEcCtD
Regorafenib—KDR—neck—melanoma	0.000258	0.0102	CbGeAlD
Regorafenib—MAPK11—head—melanoma	0.000257	0.0102	CbGeAlD
Regorafenib—EPHX2—mammalian vulva—melanoma	0.000256	0.0102	CbGeAlD
Regorafenib—Hypocalcaemia—Dactinomycin—melanoma	0.000248	0.00695	CcSEcCtD
Regorafenib—Endocrine disorder—Temozolomide—melanoma	0.000247	0.00694	CcSEcCtD
Regorafenib—Mucosal inflammation—Docetaxel—melanoma	0.000246	0.00691	CcSEcCtD
Regorafenib—FGFR2—eye—melanoma	0.000245	0.0097	CbGeAlD
Regorafenib—Liver injury—Temozolomide—melanoma	0.000244	0.00684	CcSEcCtD
Regorafenib—KIT—neck—melanoma	0.000228	0.00905	CbGeAlD
Regorafenib—FGFR1—mammalian vulva—melanoma	0.000228	0.00905	CbGeAlD
Regorafenib—Weight decreased—Vemurafenib—melanoma	0.000228	0.00639	CcSEcCtD
Regorafenib—FLT1—eye—melanoma	0.000227	0.00899	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Temozolomide—melanoma	0.000226	0.00633	CcSEcCtD
Regorafenib—RAF1—eye—melanoma	0.000225	0.00893	CbGeAlD
Regorafenib—FLT1—retina—melanoma	0.000225	0.00891	CbGeAlD
Regorafenib—Infestation NOS—Vemurafenib—melanoma	0.000225	0.0063	CcSEcCtD
Regorafenib—Infestation—Vemurafenib—melanoma	0.000225	0.0063	CcSEcCtD
Regorafenib—Polyp—Docetaxel—melanoma	0.000224	0.00629	CcSEcCtD
Regorafenib—PDGFRB—neck—melanoma	0.000223	0.00884	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.000223	0.00624	CcSEcCtD
Regorafenib—FGFR2—skin of body—melanoma	0.000213	0.00843	CbGeAlD
Regorafenib—Nail disorder—Docetaxel—melanoma	0.00021	0.0059	CcSEcCtD
Regorafenib—Cyst—Docetaxel—melanoma	0.000204	0.00572	CcSEcCtD
Regorafenib—Connective tissue disorder—Vemurafenib—melanoma	0.000198	0.00555	CcSEcCtD
Regorafenib—RAF1—skin of body—melanoma	0.000196	0.00777	CbGeAlD
Regorafenib—Neoplasm—Carmustine—melanoma	0.000192	0.00538	CcSEcCtD
Regorafenib—KDR—eye—melanoma	0.000192	0.0076	CbGeAlD
Regorafenib—EPHA2—mammalian vulva—melanoma	0.000191	0.00756	CbGeAlD
Regorafenib—Erythema multiforme—Vemurafenib—melanoma	0.000191	0.00534	CcSEcCtD
Regorafenib—DDR2—lymph node—melanoma	0.00019	0.00754	CbGeAlD
Regorafenib—KDR—retina—melanoma	0.00019	0.00753	CbGeAlD
Regorafenib—Cardiac disorder—Vemurafenib—melanoma	0.000187	0.00525	CcSEcCtD
Regorafenib—Neoplasm—Temozolomide—melanoma	0.000185	0.0052	CcSEcCtD
Regorafenib—Angiopathy—Vemurafenib—melanoma	0.000183	0.00513	CcSEcCtD
Regorafenib—Mediastinal disorder—Vemurafenib—melanoma	0.000182	0.00509	CcSEcCtD
Regorafenib—MAPK11—lymph node—melanoma	0.00018	0.00715	CbGeAlD
Regorafenib—FLT1—mammalian vulva—melanoma	0.00018	0.00713	CbGeAlD
Regorafenib—RAF1—mammalian vulva—melanoma	0.000179	0.00709	CbGeAlD
Regorafenib—Alopecia—Vemurafenib—melanoma	0.000178	0.00499	CcSEcCtD
Regorafenib—Hepatotoxicity—Docetaxel—melanoma	0.000177	0.00495	CcSEcCtD
Regorafenib—Malnutrition—Vemurafenib—melanoma	0.000175	0.00492	CcSEcCtD
Regorafenib—Myocardial ischaemia—Docetaxel—melanoma	0.00017	0.00476	CcSEcCtD
Regorafenib—Gastroenteritis—Temozolomide—melanoma	0.000168	0.00471	CcSEcCtD
Regorafenib—PDGFRB—eye—melanoma	0.000166	0.00658	CbGeAlD
Regorafenib—FLT4—head—melanoma	0.000165	0.00656	CbGeAlD
Regorafenib—Hyponatraemia—Carmustine—melanoma	0.000155	0.00434	CcSEcCtD
Regorafenib—KDR—mammalian vulva—melanoma	0.000152	0.00603	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Docetaxel—melanoma	0.00015	0.00421	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000148	0.00416	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.000148	0.00416	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000148	0.00416	CcSEcCtD
Regorafenib—ABL1—eye—melanoma	0.000148	0.00586	CbGeAlD
Regorafenib—KIT—skin of body—melanoma	0.000148	0.00586	CbGeAlD
Regorafenib—ABL1—retina—melanoma	0.000146	0.00581	CbGeAlD
Regorafenib—RET—head—melanoma	0.000146	0.00579	CbGeAlD
Regorafenib—PDGFRB—skin of body—melanoma	0.000144	0.00572	CbGeAlD
Regorafenib—Infection—Vemurafenib—melanoma	0.000142	0.00399	CcSEcCtD
Regorafenib—Nervous system disorder—Vemurafenib—melanoma	0.00014	0.00394	CcSEcCtD
Regorafenib—Hypokalaemia—Carmustine—melanoma	0.00014	0.00393	CcSEcCtD
Regorafenib—Skin disorder—Vemurafenib—melanoma	0.000139	0.0039	CcSEcCtD
Regorafenib—FGFR2—head—melanoma	0.000139	0.0055	CbGeAlD
Regorafenib—Weight decreased—Bleomycin—melanoma	0.000138	0.00387	CcSEcCtD
Regorafenib—Dry skin—Temozolomide—melanoma	0.000136	0.00383	CcSEcCtD
Regorafenib—EPHA2—head—melanoma	0.000136	0.00541	CbGeAlD
Regorafenib—Hypokalaemia—Temozolomide—melanoma	0.000135	0.0038	CcSEcCtD
Regorafenib—KIT—mammalian vulva—melanoma	0.000135	0.00534	CbGeAlD
Regorafenib—BRAF—lymph node—melanoma	0.000134	0.00533	CbGeAlD
Regorafenib—Acute coronary syndrome—Bleomycin—melanoma	0.000134	0.00376	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000134	0.00376	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Temozolomide—melanoma	0.000134	0.00376	CcSEcCtD
Regorafenib—Myocardial infarction—Bleomycin—melanoma	0.000133	0.00374	CcSEcCtD
Regorafenib—TEK—head—melanoma	0.000133	0.00528	CbGeAlD
Regorafenib—Neutropenia—Dactinomycin—melanoma	0.000133	0.00373	CcSEcCtD
Regorafenib—Stomatitis—Bleomycin—melanoma	0.000133	0.00372	CcSEcCtD
Regorafenib—PDGFRB—mammalian vulva—melanoma	0.000132	0.00522	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000131	0.00368	CcSEcCtD
Regorafenib—FLT1—head—melanoma	0.000129	0.0051	CbGeAlD
Regorafenib—ABL1—skin of body—melanoma	0.000129	0.0051	CbGeAlD
Regorafenib—EPHX2—lymph node—melanoma	0.000128	0.00509	CbGeAlD
Regorafenib—RAF1—head—melanoma	0.000128	0.00507	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000126	0.00353	CcSEcCtD
Regorafenib—Neutropenia—Carmustine—melanoma	0.000125	0.00349	CcSEcCtD
Regorafenib—Decreased appetite—Vemurafenib—melanoma	0.000124	0.00349	CcSEcCtD
Regorafenib—Stomatitis—Dactinomycin—melanoma	0.000124	0.00347	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000124	0.00347	CcSEcCtD
Regorafenib—Fatigue—Vemurafenib—melanoma	0.000123	0.00346	CcSEcCtD
Regorafenib—Neoplasm—Docetaxel—melanoma	0.000123	0.00346	CcSEcCtD
Regorafenib—Haemoglobin—Bleomycin—melanoma	0.000123	0.00344	CcSEcCtD
Regorafenib—Haemorrhage—Bleomycin—melanoma	0.000122	0.00342	CcSEcCtD
Regorafenib—PDGFRA—head—melanoma	0.000121	0.00478	CbGeAlD
Regorafenib—Neutropenia—Temozolomide—melanoma	0.00012	0.00337	CcSEcCtD
Regorafenib—ABL1—mammalian vulva—melanoma	0.000117	0.00465	CbGeAlD
Regorafenib—Weight decreased—Temozolomide—melanoma	0.000116	0.00327	CcSEcCtD
Regorafenib—FLT4—lymph node—melanoma	0.000116	0.00459	CbGeAlD
Regorafenib—Stomatitis—Carmustine—melanoma	0.000116	0.00325	CcSEcCtD
Regorafenib—Infestation—Temozolomide—melanoma	0.000115	0.00322	CcSEcCtD
Regorafenib—Infestation NOS—Temozolomide—melanoma	0.000115	0.00322	CcSEcCtD
Regorafenib—FGFR1—lymph node—melanoma	0.000114	0.00453	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000114	0.00319	CcSEcCtD
Regorafenib—Body temperature increased—Vemurafenib—melanoma	0.000113	0.00317	CcSEcCtD
Regorafenib—Stomatitis—Temozolomide—melanoma	0.000112	0.00314	CcSEcCtD
Regorafenib—KDR—head—melanoma	0.000109	0.00431	CbGeAlD
Regorafenib—Hepatobiliary disease—Temozolomide—melanoma	0.000109	0.00304	CcSEcCtD
Regorafenib—Alopecia—Bleomycin—melanoma	0.000108	0.00303	CcSEcCtD
Regorafenib—Erythema multiforme—Dactinomycin—melanoma	0.000108	0.00302	CcSEcCtD
Regorafenib—Haemoglobin—Carmustine—melanoma	0.000107	0.003	CcSEcCtD
Regorafenib—Haemorrhage—Carmustine—melanoma	0.000107	0.00299	CcSEcCtD
Regorafenib—Connective tissue disorder—Carmustine—melanoma	0.000105	0.00294	CcSEcCtD
Regorafenib—Haemoglobin—Temozolomide—melanoma	0.000104	0.0029	CcSEcCtD
Regorafenib—Haemorrhage—Temozolomide—melanoma	0.000103	0.00289	CcSEcCtD
Regorafenib—Asthenia—Vemurafenib—melanoma	0.000103	0.00288	CcSEcCtD
Regorafenib—RET—lymph node—melanoma	0.000102	0.00406	CbGeAlD
Regorafenib—Urinary tract disorder—Temozolomide—melanoma	0.000102	0.00285	CcSEcCtD
Regorafenib—Connective tissue disorder—Temozolomide—melanoma	0.000101	0.00284	CcSEcCtD
Regorafenib—Urethral disorder—Temozolomide—melanoma	0.000101	0.00283	CcSEcCtD
Regorafenib—Alopecia—Dactinomycin—melanoma	0.000101	0.00282	CcSEcCtD
Regorafenib—Hyponatraemia—Docetaxel—melanoma	9.94e-05	0.00279	CcSEcCtD
Regorafenib—Anaemia—Bleomycin—melanoma	9.82e-05	0.00276	CcSEcCtD
Regorafenib—Diarrhoea—Vemurafenib—melanoma	9.8e-05	0.00275	CcSEcCtD
Regorafenib—Erythema multiforme—Temozolomide—melanoma	9.74e-05	0.00273	CcSEcCtD
Regorafenib—KIT—head—melanoma	9.64e-05	0.00382	CbGeAlD
Regorafenib—Cardiac disorder—Temozolomide—melanoma	9.56e-05	0.00268	CcSEcCtD
Regorafenib—EPHA2—lymph node—melanoma	9.55e-05	0.00379	CbGeAlD
Regorafenib—Leukopenia—Bleomycin—melanoma	9.51e-05	0.00267	CcSEcCtD
Regorafenib—Alopecia—Carmustine—melanoma	9.42e-05	0.00264	CcSEcCtD
Regorafenib—PDGFRB—head—melanoma	9.41e-05	0.00373	CbGeAlD
Regorafenib—Angiopathy—Temozolomide—melanoma	9.34e-05	0.00262	CcSEcCtD
Regorafenib—TEK—lymph node—melanoma	9.32e-05	0.00369	CbGeAlD
Regorafenib—Mediastinal disorder—Temozolomide—melanoma	9.28e-05	0.0026	CcSEcCtD
Regorafenib—Malnutrition—Carmustine—melanoma	9.28e-05	0.0026	CcSEcCtD
Regorafenib—Anaemia—Dactinomycin—melanoma	9.16e-05	0.00257	CcSEcCtD
Regorafenib—Vomiting—Vemurafenib—melanoma	9.1e-05	0.00255	CcSEcCtD
Regorafenib—Alopecia—Temozolomide—melanoma	9.1e-05	0.00255	CcSEcCtD
Regorafenib—Dry skin—Docetaxel—melanoma	9.08e-05	0.00255	CcSEcCtD
Regorafenib—Rash—Vemurafenib—melanoma	9.03e-05	0.00253	CcSEcCtD
Regorafenib—Dermatitis—Vemurafenib—melanoma	9.02e-05	0.00253	CcSEcCtD
Regorafenib—FLT1—lymph node—melanoma	9.01e-05	0.00357	CbGeAlD
Regorafenib—Headache—Vemurafenib—melanoma	8.97e-05	0.00252	CcSEcCtD
Regorafenib—Malnutrition—Temozolomide—melanoma	8.97e-05	0.00251	CcSEcCtD
Regorafenib—RAF1—lymph node—melanoma	8.96e-05	0.00355	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Docetaxel—melanoma	8.92e-05	0.0025	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Docetaxel—melanoma	8.92e-05	0.0025	CcSEcCtD
Regorafenib—Leukopenia—Dactinomycin—melanoma	8.87e-05	0.00249	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Docetaxel—melanoma	8.73e-05	0.00245	CcSEcCtD
Regorafenib—Tremor—Carmustine—melanoma	8.69e-05	0.00244	CcSEcCtD
Regorafenib—ABCB1—blood vessel—melanoma	8.64e-05	0.00342	CbGeAlD
Regorafenib—Infection—Bleomycin—melanoma	8.62e-05	0.00242	CcSEcCtD
Regorafenib—Anaemia—Carmustine—melanoma	8.58e-05	0.00241	CcSEcCtD
Regorafenib—Nausea—Vemurafenib—melanoma	8.5e-05	0.00239	CcSEcCtD
Regorafenib—Thrombocytopenia—Bleomycin—melanoma	8.49e-05	0.00238	CcSEcCtD
Regorafenib—PDGFRA—lymph node—melanoma	8.44e-05	0.00335	CbGeAlD
Regorafenib—Tremor—Temozolomide—melanoma	8.4e-05	0.00236	CcSEcCtD
Regorafenib—ABL1—head—melanoma	8.39e-05	0.00333	CbGeAlD
Regorafenib—Leukopenia—Carmustine—melanoma	8.31e-05	0.00233	CcSEcCtD
Regorafenib—Anaemia—Temozolomide—melanoma	8.29e-05	0.00232	CcSEcCtD
Regorafenib—Infection—Dactinomycin—melanoma	8.04e-05	0.00225	CcSEcCtD
Regorafenib—Leukopenia—Temozolomide—melanoma	8.03e-05	0.00225	CcSEcCtD
Regorafenib—Hypertension—Carmustine—melanoma	8.01e-05	0.00225	CcSEcCtD
Regorafenib—Neutropenia—Docetaxel—melanoma	8e-05	0.00224	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—melanoma	7.92e-05	0.00222	CcSEcCtD
Regorafenib—Weight decreased—Docetaxel—melanoma	7.74e-05	0.00217	CcSEcCtD
Regorafenib—Hypertension—Temozolomide—melanoma	7.74e-05	0.00217	CcSEcCtD
Regorafenib—Infestation NOS—Docetaxel—melanoma	7.63e-05	0.00214	CcSEcCtD
Regorafenib—Infestation—Docetaxel—melanoma	7.63e-05	0.00214	CcSEcCtD
Regorafenib—KDR—lymph node—melanoma	7.62e-05	0.00302	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	7.58e-05	0.00213	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Docetaxel—melanoma	7.56e-05	0.00212	CcSEcCtD
Regorafenib—Decreased appetite—Bleomycin—melanoma	7.54e-05	0.00212	CcSEcCtD
Regorafenib—Infection—Carmustine—melanoma	7.52e-05	0.00211	CcSEcCtD
Regorafenib—Acute coronary syndrome—Docetaxel—melanoma	7.52e-05	0.00211	CcSEcCtD
Regorafenib—CYP2B6—skin of body—melanoma	7.48e-05	0.00297	CbGeAlD
Regorafenib—Myocardial infarction—Docetaxel—melanoma	7.48e-05	0.0021	CcSEcCtD
Regorafenib—Dry mouth—Temozolomide—melanoma	7.47e-05	0.00209	CcSEcCtD
Regorafenib—Stomatitis—Docetaxel—melanoma	7.44e-05	0.00209	CcSEcCtD
Regorafenib—Pain—Bleomycin—melanoma	7.42e-05	0.00208	CcSEcCtD
Regorafenib—Thrombocytopenia—Carmustine—melanoma	7.41e-05	0.00208	CcSEcCtD
Regorafenib—ABCG2—mammalian vulva—melanoma	7.4e-05	0.00293	CbGeAlD
Regorafenib—Infection—Temozolomide—melanoma	7.27e-05	0.00204	CcSEcCtD
Regorafenib—Hepatobiliary disease—Docetaxel—melanoma	7.22e-05	0.00202	CcSEcCtD
Regorafenib—Nervous system disorder—Temozolomide—melanoma	7.18e-05	0.00201	CcSEcCtD
Regorafenib—Thrombocytopenia—Temozolomide—melanoma	7.16e-05	0.00201	CcSEcCtD
Regorafenib—Skin disorder—Temozolomide—melanoma	7.11e-05	0.00199	CcSEcCtD
Regorafenib—Decreased appetite—Dactinomycin—melanoma	7.03e-05	0.00197	CcSEcCtD
Regorafenib—Fatigue—Dactinomycin—melanoma	6.98e-05	0.00196	CcSEcCtD
Regorafenib—Pain—Dactinomycin—melanoma	6.92e-05	0.00194	CcSEcCtD
Regorafenib—Haemoglobin—Docetaxel—melanoma	6.88e-05	0.00193	CcSEcCtD
Regorafenib—Body temperature increased—Bleomycin—melanoma	6.86e-05	0.00192	CcSEcCtD
Regorafenib—Haemorrhage—Docetaxel—melanoma	6.85e-05	0.00192	CcSEcCtD
Regorafenib—Urinary tract disorder—Docetaxel—melanoma	6.76e-05	0.0019	CcSEcCtD
Regorafenib—KIT—lymph node—melanoma	6.75e-05	0.00268	CbGeAlD
Regorafenib—Connective tissue disorder—Docetaxel—melanoma	6.73e-05	0.00189	CcSEcCtD
Regorafenib—Urethral disorder—Docetaxel—melanoma	6.71e-05	0.00188	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—melanoma	6.62e-05	0.00186	CcSEcCtD
Regorafenib—PDGFRB—lymph node—melanoma	6.59e-05	0.00261	CbGeAlD
Regorafenib—Decreased appetite—Carmustine—melanoma	6.58e-05	0.00185	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Carmustine—melanoma	6.54e-05	0.00183	CcSEcCtD
Regorafenib—Erythema multiforme—Docetaxel—melanoma	6.48e-05	0.00182	CcSEcCtD
Regorafenib—Pain—Carmustine—melanoma	6.48e-05	0.00182	CcSEcCtD
Regorafenib—Abdominal pain—Dactinomycin—melanoma	6.4e-05	0.00179	CcSEcCtD
Regorafenib—Body temperature increased—Dactinomycin—melanoma	6.4e-05	0.00179	CcSEcCtD
Regorafenib—Decreased appetite—Temozolomide—melanoma	6.36e-05	0.00178	CcSEcCtD
Regorafenib—Cardiac disorder—Docetaxel—melanoma	6.36e-05	0.00178	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Temozolomide—melanoma	6.32e-05	0.00177	CcSEcCtD
Regorafenib—Fatigue—Temozolomide—melanoma	6.31e-05	0.00177	CcSEcCtD
Regorafenib—Pain—Temozolomide—melanoma	6.26e-05	0.00176	CcSEcCtD
Regorafenib—Sorafenib—ABCB1—melanoma	6.24e-05	0.035	CrCbGaD
Regorafenib—Asthenia—Bleomycin—melanoma	6.22e-05	0.00175	CcSEcCtD
Regorafenib—Angiopathy—Docetaxel—melanoma	6.21e-05	0.00174	CcSEcCtD
Regorafenib—Gastrointestinal pain—Carmustine—melanoma	6.19e-05	0.00174	CcSEcCtD
Regorafenib—Mediastinal disorder—Docetaxel—melanoma	6.17e-05	0.00173	CcSEcCtD
Regorafenib—Alopecia—Docetaxel—melanoma	6.05e-05	0.0017	CcSEcCtD
Regorafenib—Body temperature increased—Carmustine—melanoma	5.99e-05	0.00168	CcSEcCtD
Regorafenib—Abdominal pain—Carmustine—melanoma	5.99e-05	0.00168	CcSEcCtD
Regorafenib—Gastrointestinal pain—Temozolomide—melanoma	5.98e-05	0.00168	CcSEcCtD
Regorafenib—Malnutrition—Docetaxel—melanoma	5.96e-05	0.00167	CcSEcCtD
Regorafenib—ABL1—lymph node—melanoma	5.88e-05	0.00233	CbGeAlD
Regorafenib—Asthenia—Dactinomycin—melanoma	5.8e-05	0.00163	CcSEcCtD
Regorafenib—Abdominal pain—Temozolomide—melanoma	5.78e-05	0.00162	CcSEcCtD
Regorafenib—Body temperature increased—Temozolomide—melanoma	5.78e-05	0.00162	CcSEcCtD
Regorafenib—Diarrhoea—Dactinomycin—melanoma	5.54e-05	0.00155	CcSEcCtD
Regorafenib—Vomiting—Bleomycin—melanoma	5.52e-05	0.00155	CcSEcCtD
Regorafenib—Anaemia—Docetaxel—melanoma	5.51e-05	0.00155	CcSEcCtD
Regorafenib—Rash—Bleomycin—melanoma	5.47e-05	0.00153	CcSEcCtD
Regorafenib—Dermatitis—Bleomycin—melanoma	5.46e-05	0.00153	CcSEcCtD
Regorafenib—Asthenia—Carmustine—melanoma	5.43e-05	0.00152	CcSEcCtD
Regorafenib—Leukopenia—Docetaxel—melanoma	5.34e-05	0.0015	CcSEcCtD
Regorafenib—Asthenia—Temozolomide—melanoma	5.25e-05	0.00147	CcSEcCtD
Regorafenib—Diarrhoea—Carmustine—melanoma	5.18e-05	0.00145	CcSEcCtD
Regorafenib—Nausea—Bleomycin—melanoma	5.15e-05	0.00145	CcSEcCtD
Regorafenib—Hypertension—Docetaxel—melanoma	5.15e-05	0.00144	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—melanoma	5.14e-05	0.00144	CcSEcCtD
Regorafenib—Rash—Dactinomycin—melanoma	5.1e-05	0.00143	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	5.04e-05	0.00141	CcSEcCtD
Regorafenib—Diarrhoea—Temozolomide—melanoma	5.01e-05	0.0014	CcSEcCtD
Regorafenib—Dry mouth—Docetaxel—melanoma	4.96e-05	0.00139	CcSEcCtD
Regorafenib—CYP2B6—head—melanoma	4.88e-05	0.00194	CbGeAlD
Regorafenib—Infection—Docetaxel—melanoma	4.83e-05	0.00136	CcSEcCtD
Regorafenib—Vomiting—Carmustine—melanoma	4.81e-05	0.00135	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—melanoma	4.81e-05	0.00135	CcSEcCtD
Regorafenib—Rash—Carmustine—melanoma	4.77e-05	0.00134	CcSEcCtD
Regorafenib—Nervous system disorder—Docetaxel—melanoma	4.77e-05	0.00134	CcSEcCtD
Regorafenib—Dermatitis—Carmustine—melanoma	4.77e-05	0.00134	CcSEcCtD
Regorafenib—Thrombocytopenia—Docetaxel—melanoma	4.76e-05	0.00134	CcSEcCtD
Regorafenib—Headache—Carmustine—melanoma	4.74e-05	0.00133	CcSEcCtD
Regorafenib—Skin disorder—Docetaxel—melanoma	4.73e-05	0.00133	CcSEcCtD
Regorafenib—Vomiting—Temozolomide—melanoma	4.65e-05	0.0013	CcSEcCtD
Regorafenib—Rash—Temozolomide—melanoma	4.61e-05	0.00129	CcSEcCtD
Regorafenib—Dermatitis—Temozolomide—melanoma	4.61e-05	0.00129	CcSEcCtD
Regorafenib—Headache—Temozolomide—melanoma	4.58e-05	0.00129	CcSEcCtD
Regorafenib—ABCB1—retina—melanoma	4.55e-05	0.00181	CbGeAlD
Regorafenib—Nausea—Carmustine—melanoma	4.5e-05	0.00126	CcSEcCtD
Regorafenib—Nausea—Temozolomide—melanoma	4.35e-05	0.00122	CcSEcCtD
Regorafenib—Decreased appetite—Docetaxel—melanoma	4.23e-05	0.00119	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Docetaxel—melanoma	4.2e-05	0.00118	CcSEcCtD
Regorafenib—Fatigue—Docetaxel—melanoma	4.2e-05	0.00118	CcSEcCtD
Regorafenib—Pain—Docetaxel—melanoma	4.16e-05	0.00117	CcSEcCtD
Regorafenib—Gastrointestinal pain—Docetaxel—melanoma	3.98e-05	0.00112	CcSEcCtD
Regorafenib—Abdominal pain—Docetaxel—melanoma	3.85e-05	0.00108	CcSEcCtD
Regorafenib—Body temperature increased—Docetaxel—melanoma	3.85e-05	0.00108	CcSEcCtD
Regorafenib—ABCG2—lymph node—melanoma	3.7e-05	0.00147	CbGeAlD
Regorafenib—ABCB1—mammalian vulva—melanoma	3.65e-05	0.00145	CbGeAlD
Regorafenib—Asthenia—Docetaxel—melanoma	3.49e-05	0.000979	CcSEcCtD
Regorafenib—Diarrhoea—Docetaxel—melanoma	3.33e-05	0.000934	CcSEcCtD
Regorafenib—Vomiting—Docetaxel—melanoma	3.09e-05	0.000868	CcSEcCtD
Regorafenib—Rash—Docetaxel—melanoma	3.07e-05	0.000861	CcSEcCtD
Regorafenib—Dermatitis—Docetaxel—melanoma	3.07e-05	0.00086	CcSEcCtD
Regorafenib—Headache—Docetaxel—melanoma	3.05e-05	0.000855	CcSEcCtD
Regorafenib—Nausea—Docetaxel—melanoma	2.89e-05	0.000811	CcSEcCtD
Regorafenib—ABCB1—head—melanoma	2.61e-05	0.00103	CbGeAlD
Regorafenib—ABCB1—lymph node—melanoma	1.83e-05	0.000724	CbGeAlD
Regorafenib—PDGFRA—Immune System—IL6—melanoma	3.32e-07	4.67e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—melanoma	3.32e-07	4.66e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—melanoma	3.31e-07	4.65e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PIK3CA—melanoma	3.31e-07	4.65e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—melanoma	3.3e-07	4.64e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NRAS—melanoma	3.3e-07	4.64e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—melanoma	3.3e-07	4.64e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PIK3CA—melanoma	3.3e-07	4.63e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—melanoma	3.3e-07	4.63e-06	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—AKT1—melanoma	3.3e-07	4.63e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—PIK3CA—melanoma	3.3e-07	4.63e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—melanoma	3.29e-07	4.63e-06	CbGpPWpGaD
Regorafenib—BRAF—Disease—AKT1—melanoma	3.29e-07	4.62e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MDM2—melanoma	3.29e-07	4.62e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—melanoma	3.28e-07	4.61e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—melanoma	3.28e-07	4.61e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—melanoma	3.28e-07	4.61e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK1—melanoma	3.28e-07	4.6e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—melanoma	3.28e-07	4.6e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.27e-07	4.59e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—melanoma	3.25e-07	4.57e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK1—melanoma	3.25e-07	4.56e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—melanoma	3.25e-07	4.56e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—melanoma	3.24e-07	4.55e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—melanoma	3.24e-07	4.55e-06	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—melanoma	3.24e-07	4.55e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB2—melanoma	3.24e-07	4.55e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—melanoma	3.24e-07	4.55e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—melanoma	3.21e-07	4.52e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—melanoma	3.21e-07	4.51e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK1—melanoma	3.21e-07	4.51e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—melanoma	3.21e-07	4.5e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—melanoma	3.21e-07	4.5e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—melanoma	3.2e-07	4.49e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CB—melanoma	3.2e-07	4.49e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CG—melanoma	3.19e-07	4.48e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—melanoma	3.18e-07	4.47e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK3—melanoma	3.16e-07	4.44e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—melanoma	3.13e-07	4.4e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—melanoma	3.12e-07	4.39e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—melanoma	3.12e-07	4.38e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—melanoma	3.12e-07	4.38e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—melanoma	3.11e-07	4.37e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1A—melanoma	3.11e-07	4.36e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK3—melanoma	3.11e-07	4.36e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—melanoma	3.1e-07	4.35e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—melanoma	3.1e-07	4.35e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—melanoma	3.09e-07	4.35e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—melanoma	3.08e-07	4.33e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NFKB1—melanoma	3.08e-07	4.33e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PPARG—melanoma	3.08e-07	4.33e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PRKCA—melanoma	3.08e-07	4.32e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—melanoma	3.08e-07	4.32e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—melanoma	3.08e-07	4.32e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—melanoma	3.08e-07	4.32e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—melanoma	3.08e-07	4.32e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—melanoma	3.07e-07	4.32e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—melanoma	3.07e-07	4.32e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—melanoma	3.07e-07	4.31e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—melanoma	3.07e-07	4.31e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—melanoma	3.07e-07	4.31e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—melanoma	3.07e-07	4.31e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—melanoma	3.06e-07	4.3e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ERCC2—melanoma	3.05e-07	4.29e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—melanoma	3.05e-07	4.29e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—melanoma	3.05e-07	4.28e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—melanoma	3.05e-07	4.28e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—melanoma	3.05e-07	4.28e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—melanoma	3.03e-07	4.26e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—melanoma	3.02e-07	4.24e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—melanoma	3.01e-07	4.23e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK1—melanoma	3.01e-07	4.23e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—melanoma	3.01e-07	4.23e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PRKCA—melanoma	3e-07	4.22e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—melanoma	3e-07	4.21e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—melanoma	2.99e-07	4.21e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—melanoma	2.99e-07	4.2e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ERCC2—melanoma	2.98e-07	4.19e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK1—melanoma	2.95e-07	4.15e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—melanoma	2.95e-07	4.15e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK3—melanoma	2.95e-07	4.14e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—melanoma	2.94e-07	4.13e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK3—melanoma	2.94e-07	4.13e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—melanoma	2.94e-07	4.12e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—melanoma	2.93e-07	4.11e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—melanoma	2.92e-07	4.1e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—melanoma	2.92e-07	4.1e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP17A1—melanoma	2.9e-07	4.08e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—melanoma	2.89e-07	4.06e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—melanoma	2.88e-07	4.05e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—melanoma	2.87e-07	4.03e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—melanoma	2.86e-07	4.02e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—melanoma	2.86e-07	4.02e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—melanoma	2.86e-07	4.02e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—melanoma	2.84e-07	3.99e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—melanoma	2.84e-07	3.99e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—melanoma	2.84e-07	3.99e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—melanoma	2.83e-07	3.98e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.83e-07	3.98e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—melanoma	2.83e-07	3.98e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—melanoma	2.82e-07	3.96e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PRKCA—melanoma	2.81e-07	3.94e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CD—melanoma	2.8e-07	3.94e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK1—melanoma	2.8e-07	3.94e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—melanoma	2.8e-07	3.94e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—melanoma	2.8e-07	3.93e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK1—melanoma	2.8e-07	3.93e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—melanoma	2.8e-07	3.93e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—melanoma	2.79e-07	3.92e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—melanoma	2.79e-07	3.92e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ERCC2—melanoma	2.78e-07	3.91e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—melanoma	2.78e-07	3.91e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—melanoma	2.78e-07	3.9e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—melanoma	2.77e-07	3.89e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1A—melanoma	2.77e-07	3.89e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—melanoma	2.77e-07	3.89e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—melanoma	2.77e-07	3.88e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—melanoma	2.76e-07	3.88e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—melanoma	2.76e-07	3.88e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—melanoma	2.76e-07	3.88e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—melanoma	2.75e-07	3.86e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NFKB1—melanoma	2.75e-07	3.86e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GNA11—melanoma	2.74e-07	3.85e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—melanoma	2.72e-07	3.83e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—melanoma	2.7e-07	3.79e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CG—melanoma	2.7e-07	3.79e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—melanoma	2.69e-07	3.79e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—melanoma	2.69e-07	3.78e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—FASN—melanoma	2.68e-07	3.77e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—melanoma	2.67e-07	3.75e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—melanoma	2.65e-07	3.72e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK3—melanoma	2.65e-07	3.72e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—melanoma	2.64e-07	3.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC5A5—melanoma	2.64e-07	3.71e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—melanoma	2.63e-07	3.7e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—melanoma	2.61e-07	3.67e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARG—melanoma	2.61e-07	3.66e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—melanoma	2.61e-07	3.66e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—melanoma	2.58e-07	3.62e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—melanoma	2.57e-07	3.62e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—melanoma	2.56e-07	3.6e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—melanoma	2.55e-07	3.58e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GNAQ—melanoma	2.55e-07	3.58e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CD44—melanoma	2.55e-07	3.58e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.53e-07	3.55e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—melanoma	2.53e-07	3.55e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK1—melanoma	2.52e-07	3.54e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—melanoma	2.52e-07	3.54e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—melanoma	2.52e-07	3.54e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—melanoma	2.5e-07	3.51e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—melanoma	2.49e-07	3.5e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—melanoma	2.48e-07	3.48e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—melanoma	2.47e-07	3.47e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—melanoma	2.46e-07	3.46e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—melanoma	2.46e-07	3.46e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—melanoma	2.46e-07	3.46e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CB—melanoma	2.44e-07	3.43e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1B1—melanoma	2.44e-07	3.43e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—melanoma	2.43e-07	3.42e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—melanoma	2.43e-07	3.41e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—melanoma	2.42e-07	3.4e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—melanoma	2.42e-07	3.39e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CG—melanoma	2.41e-07	3.39e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—melanoma	2.4e-07	3.37e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—melanoma	2.4e-07	3.37e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—melanoma	2.38e-07	3.34e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CD—melanoma	2.37e-07	3.34e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—melanoma	2.37e-07	3.33e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK3—melanoma	2.36e-07	3.32e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—melanoma	2.35e-07	3.31e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CG—melanoma	2.35e-07	3.31e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—melanoma	2.35e-07	3.3e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—melanoma	2.34e-07	3.29e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARG—melanoma	2.33e-07	3.27e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—melanoma	2.32e-07	3.26e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—melanoma	2.31e-07	3.25e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.31e-07	3.24e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—melanoma	2.3e-07	3.23e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—melanoma	2.3e-07	3.22e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—melanoma	2.27e-07	3.19e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARG—melanoma	2.27e-07	3.19e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—melanoma	2.27e-07	3.19e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—melanoma	2.25e-07	3.16e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK1—melanoma	2.25e-07	3.15e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—melanoma	2.25e-07	3.15e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—melanoma	2.25e-07	3.15e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CG—melanoma	2.2e-07	3.09e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	2.19e-07	3.07e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—melanoma	2.15e-07	3.03e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—melanoma	2.15e-07	3.02e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—melanoma	2.13e-07	3e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARG—melanoma	2.12e-07	2.98e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—melanoma	2.12e-07	2.98e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CD—melanoma	2.12e-07	2.98e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—melanoma	2.12e-07	2.97e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—melanoma	2.11e-07	2.97e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—melanoma	2.09e-07	2.94e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—melanoma	2.09e-07	2.94e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CB—melanoma	2.07e-07	2.91e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CD—melanoma	2.07e-07	2.91e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—melanoma	2.05e-07	2.88e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—melanoma	2.04e-07	2.87e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—melanoma	2.03e-07	2.86e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—melanoma	2.02e-07	2.84e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—melanoma	2.01e-07	2.83e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—melanoma	1.99e-07	2.79e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—melanoma	1.98e-07	2.79e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—melanoma	1.96e-07	2.75e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—melanoma	1.96e-07	2.75e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—melanoma	1.95e-07	2.74e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—melanoma	1.94e-07	2.72e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CD—melanoma	1.93e-07	2.71e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—melanoma	1.91e-07	2.68e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—melanoma	1.89e-07	2.65e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PRKCA—melanoma	1.85e-07	2.6e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CB—melanoma	1.85e-07	2.59e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ERCC2—melanoma	1.84e-07	2.58e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—melanoma	1.83e-07	2.57e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—melanoma	1.8e-07	2.53e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CB—melanoma	1.8e-07	2.53e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—melanoma	1.79e-07	2.51e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—melanoma	1.79e-07	2.51e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—melanoma	1.79e-07	2.51e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—melanoma	1.73e-07	2.42e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CB—melanoma	1.68e-07	2.37e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—melanoma	1.67e-07	2.34e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—melanoma	1.66e-07	2.33e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—melanoma	1.6e-07	2.24e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—melanoma	1.59e-07	2.24e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—melanoma	1.56e-07	2.19e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—melanoma	1.49e-07	2.09e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—melanoma	1.46e-07	2.04e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CG—melanoma	1.45e-07	2.04e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARG—melanoma	1.4e-07	1.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CD—melanoma	1.27e-07	1.79e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—melanoma	1.26e-07	1.77e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—melanoma	1.26e-07	1.77e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—melanoma	1.22e-07	1.71e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—melanoma	1.13e-07	1.58e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CB—melanoma	1.11e-07	1.56e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—melanoma	1.1e-07	1.55e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—melanoma	1.1e-07	1.54e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—melanoma	1.03e-07	1.45e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—melanoma	1.03e-07	1.44e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—melanoma	9.6e-08	1.35e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—melanoma	9.2e-08	1.29e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—melanoma	8.98e-08	1.26e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—melanoma	8.39e-08	1.18e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—melanoma	6.77e-08	9.51e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—melanoma	5.53e-08	7.77e-07	CbGpPWpGaD
